Using a new treatment to improve outcomes for glioblastoma patients
Official title: NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma
Funded at Mayo Clinic Rochester · NIH-11048007 · Data updated 2026-11-12
This study is looking at a new treatment called NT-I7 that might help boost the immune system in people with glioblastoma by working alongside another therapy, and it aims to increase the number of important immune cells to better fight the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $639,004 |
| NIH project number | 1R01CA288862-01A1 |
| Project ID | NIH-11048007 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have undergone standard treatments like radiation and temozolomide.
✕Less likely to help
Patients with glioblastoma who are not eligible for immunotherapy or have contraindications to the treatments being tested may not benefit from this research.
What this research studies
This research investigates the use of NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade to enhance the immune response in patients with glioblastoma. The study aims to address the issue of treatment-related lymphopenia, which can hinder the effectiveness of immunotherapy. By administering NT-I7, the researchers hope to increase the number of immune cells, particularly CD8 T cells, which are crucial for fighting tumors. The approach has shown promise in preclinical models and has been well-tolerated in early human trials.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better responses to immunotherapy for glioblastoma patients.
How similar studies have gone: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel combination treatment.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Campian, Jian — Mayo Clinic Rochester
- Study coordinator: Campian, Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.